IRCT138710181531N1已完成未知
A randomized placebo-controlled trial to determine the effect of iron supplementation on hematological indices in pregnant women with hemoglobin =13.2 g/dl
Tarbiat Modarres University0 个研究点目标入组 87 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 17 years 至 35 years（—）
- 性别
- Female
入选标准
- •Pregnant women with Hb = 13.2 g/dl in the early stage of the second trimester, body mass index (BMI) between 19.8 and 26 kg/m2, single pregnancy, age between 17 and 35 years
- •Exclusion criteria: Falling Hb to less than 10.5 g/dl in the second trimester or 11 g/dl in the third trimester, history of any renal, hepatic, thyroid, or cardiac diseases, presence of diabetes, asthma, hypertension, or inflammatory diseases, presence of severe nausea and vomiting of pregnancy, smoking, substance abuse, history of threatened abortion
排除标准
- 未提供
研究者
相似试验
已完成
3 期
MObILE study - Midodrine effect on Orthostatic IntoLErance after hip and knee replacementsOrthostatic HypotensionACTRN12620001342909Waitemata District Health Board170
已完成
不适用
A randomised controlled trial investigating the effectiveness of pulsed electrical stimulation in treating osteoarthritis of the kneeOstearthritis of the kneeMusculoskeletal - OsteoarthritisACTRN12607000492459Robyn Fary70
已完成
2 期
The effects of nigella sativa oil on rheumatoid arthritis treatmentRheumatoid arthritis.Rheumatoid arthritis, unspecifiedIRCT2012120811689N1Vice chancellor for Research, Tabriz University of Medical Sciences50
尚未招募
2 期
Study to evaluate the efficacy of Parikara Yoga (An Ayurvedic polyherbal formulation) and Dietary regimen in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)CTRI/2023/08/055977ational Institute of Ayurveda Deemed to be University, Jaipur
进行中（未招募）
不适用
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), onprogression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.EUCTR2008-001736-12-BEF. Hoffmann-La Roche Ltd150